Nörokütan Hastalıkların Endokrin Bulguları ve Yönetimi
Özet
Nörokutan hastalıklar, multisistemik etkileriyle büyüme geriliği, puberte bozuklukları ve tiroid disfonksiyonu gibi çeşitli endokrin patolojilerin eşlik edebildiği karmaşık klinik tablolardır. Bu hastaların yönetiminde endokrin sistemin sistematik olarak izlenmesi, komplikasyonların erken tespiti ve yaşam kalitesinin korunması açısından kritik öneme sahiptir. Tanı kriterleri arasında yer almasalar da, eşlik eden endokrin sorunların düzenli takibi tedavi başarısı ve hasta sağlığı için vazgeçilmezdir.
Neurocutaneous diseases are multisystemic disorders that frequently present with associated endocrine pathologies, including growth disturbances, puberty irregularities, and thyroid dysfunction. Systematic endocrine monitoring during clinical management is essential for the early detection of these complications and for optimizing long-term patient outcomes. Although not always part of formal diagnostic criteria, the proactive evaluation of endocrine function is vital for effective care and the prevention of secondary health issues in affected individuals.
Referanslar
Yarar C. Nörofibromatozlar. Çarman KB, editör. Nörokütanöz Hastalıklar. 1. Baskı. Ankara: Türkiye Klinikleri; 2021. p.101-13.
Ly KI, Blakeley JO. The Diagnosis and Management of Neurofibromatosis Type 1. Med Clin North Am. 2019;103(6):1035-54.
Giugliano T, Santoro C, Torella A, et al. Clinical and Genetic Findings in Children with Neurofibromatosis Type 1, Legius Syndrome, and Other Related Neurocutaneous Disorders. Genes (Basel). 2019;10(8):580.
Carmi D, Shohat M, Metzker A, Dickerman Z. Growth, puberty, and endocrine functions in patients with sporadic or familial neurofibromatosis type 1: a longitudinal study. Pediatrics. 1999;103(6 Pt 1):1257-62.
Josefson J, Listernick R, Fangusaro JR, Charrow J, Habiby R. Growth hormone excess in children with neurofibromatosis type 1-associated and sporadic optic pathway tumors. J Pediatr. 2011;158(3):433-6.
Blackburn J, Didi M, Avula S, Senniappan S. Isolated premature menarche in two siblings with Neurofibromatosis type 1. J Pediatr Endocrinol Metab. 2020;33(6):813-16.
Virdis R, Street ME, Bandello MA, et al. Growth and pubertal disorders in neurofibromatosis type 1. J Pediatr Endocrinol Metab. 2003;16 Suppl 2:289-92.
Yao Z, Guo D, Li H et al. Surgical Treatment of Dystrophic Scoliosis in Neurofibromatosis Type 1: Outcomes and Complications. Clin Spine Surg. 2019;32(1):E50-E55.
Heervä E, Leinonen P, Kuorilehto T, et.al. Neurofibromatosis 1-related osteopenia often progresses to osteoporosis in 12 years. Calcif Tissue Int. 2013;92(1):23-7.
Öztürk S, Samur MB, Canpolat M. Tüberoz skleroz kompleksi. Çarman KB, editör. Nörokütanöz Hastalıklar. 1. Baskı. Ankara: Türkiye Klinikleri; 2021. p.114-31.
Randle SC. Tuberous Sclerosis Complex: A Review. Pediatr Ann. 2017;46(4):e166-e171.
Lodish MB, Stratakis CA. Endocrine tumours in neurofibromatosis type 1, tuberous sclerosis and related syndromes. Best Pract Res Clin Endocrinol Metab. 2010;24(3):439-49.
Auladell M, Boronat S, Barber I, Thiele EA. Thyroid nodules on chest CT of patients with tuberous sclerosis complex. Am J Med Genet A. 2015;167A(12):2992-7.
Mehta S, Rusyn L, Ginsburg H, Hajdu C, Kohn B. Pancreatic Neuroendocrine Tumor in a Young Child With Tuberous Sclerosis Complex 1. J Endocr Soc. 2019;3(6):1201-06.
Güler S. Sturge-Weber sendromu. Çarman KB, editör. Nörokütanöz Hastalıklar. 1. Baskı. Ankara: Türkiye Klinikleri; 2021. p.132-8.
Sudarsanam A, Ardern-Holmes SL. Sturge-Weber syndrome: from the past to the present. Eur J Paediatr Neurol. 2014;18(3):257-66.
Miller RS, Ball KL, Comi AM, Germain-Lee EL. Growth hormone deficiency in SturgeeWeber syndrome. Arch Dis Child 2006;91:340e1.
Comi AM, Bellamkonda S, Ferenc LM, Cohen BA, Germain- Lee EL. Central hypothyroidism and SturgeeWeber syndrome. Pediatr Neurol 2008;39:58e62.
Saroj G, Gangwar A, Dhillon JK. Hypothyroidism and Sturge-Weber Syndrome associated with Bilateral Port-wine Nevus. Int J Clin Pediatr Dent. 2016;9(1):82-5.
Gençpınar P, Olgaç Dündar N. Hipomelanozis İto. Çarman KB, editör. Nörokütanöz Hastalıklar. 1. Baskı. Ankara: Türkiye Klinikleri; 2021. p.154-8.
Ream M. Hypomelanosis of Ito. Handb Clin Neurol. 2015;132:281-9.
Ruggieri M, Pavone L. Hypomelanosis of Ito: clinical syndrome or just phenotype? J Child Neurol. 2000;15(10):635-44.
Gazeteci Tekin H. Sjögren-larsson Sendromu. Çarman KB, editör. Nörokütanöz Hastalıklar. 1. Baskı. Ankara: Türkiye Klinikleri; 2021. p.159-63.
Bindu PS. Sjogren-Larsson Syndrome: Mechanisms and Management. Appl Clin Genet. 2020;13:13-24.
Staps P, van Gaalen J, van Domburg P, et al. Sjogren-Larsson syndrome: The mild end of the phenotypic spectrum. JIMD Rep. 2020;53(1):61-70.
İnce H. Von Hippel-Lindau hastalığı. Çarman KB, editör. Nörokütanöz Hastalıklar. 1. Baskı. Ankara: Türkiye Klinikleri; 2021. p.199-206.
Aronow ME, Wiley HE, Gaudric A ,et.al. Von Hippel-Landau Disease:Update on Pathogenesis and Systemic Aspects. Retina. 2019;39(12):2243-53.
Pradhan R, George N, Mandal K, Agarwal A, Gupta SK. Endocrine Manifestations of Von Hippel-Landau Disease. Indian J Endocrinol Metab. 2019;23(1):159-64.
Cassol C, Mete O. Endocrine manifestations of von Hippel-Lindau disease. Arch Pathol Lab Med. 2015;139(2):263-8.
Gönüllü Polat B, Kömür M. Serebrotendinoz ksantomatozis. Çarman KB, editör. Nörokütanöz Hastalıklar. 1. Baskı. Ankara: Türkiye Klinikleri; 2021. p.193-8.
Nie S, Chen G, Cao X, Zhang Y. Cerebrotendinous xanthomatosis: a comprehensive review of pathogenesis, clinical manifestations, diagnosis, and management. Orphanet J Rare Dis. 2014;9:179.
Serin HM, Şimşek E. Ataksi telenjiektazi. Çarman KB, editör. Nörokütanöz Hastalıklar. 1. Baskı. Ankara: Türkiye Klinikleri; 2021. p.187- 92.
Rothblum-Oviatt C, Wright J, Lefton-Greif MA, McGrath-Morrow SA, Crawford TO, Lederman HM. Ataxia telangiectasia: a review. Orphanet J Rare Dis. 2016;11(1):159.
Nissenkorn A, Levy-Shraga Y, Banet-Levi Y, Lahad A, Sarouk I, Modan-Moses D. Endocrine abnormalities in ataxia telangiectasia: findings from a national cohort. Pediatr Res. 2016;79(6):889-94.
Voss S, Pietzner J, Hoche F, et. al. Growth retardation and growth hormone deficiency in patients with Ataxia telangiectasia. Growth Factors. 2014;32(3-4):123-9
Donath H, Hess U, Kieslich M, et. al. Diabetes in Patients With Ataxia Telangiectasia: A National Cohort Study. Front Pediatr. 2020 Jul;8:317.
Moog U. Encephalocraniocutaneous lipomatosis. J Med Genet. 2009;46(11):721-9.
Koçak O. Ensefalokraniokutanöz lipomatozis. Çarman KB, editör. Nörokütanöz Hastalıklar. 1. Baskı. Ankara: Türkiye Klinikleri; 2021. p.183-6.
Bamforth JS, Riccardi VM, Thisen P, et.al. Encephalocraniocutaneous lipomatosis. Report of two cases and a review of the literature. Neurofibromatosis. 1989;2(3):166-73.
Rocha RCC, Estrella MPS, Amaral DMD, Barbosa AM, Abreu MAMM. Proteus syndrome. An Bras Dermatol. 2017;92(5):717-20.
Işıkay S. Proteus sendromu. Çarman KB, editör. Nörokütanöz Hastalıklar. 1. Baskı. Ankara: Türkiye Klinikleri; 2021. p.164-9.
Frydman M, Kauschansky A, Vrsano I. Ambiguous genitalia in the Proteus syndrome. Am J Med Genet. 1990;36(4):511-2.
Molière S, Mathelin C. The Cowden Syndrome. N Engl J Med. 2020;382(15):e29.
Ünver O, Özgen Z. Cowden sendromu. Çarman KB, editör. Nörokütanöz Hastalıklar. 1. Baskı. Ankara: Türkiye Klinikleri; 2021. p.177- 82.
Hall JE, Abdollahian DJ, Sinard RJ. Thyroid disease associated with Cowden syndrome: A meta-analysis. Head Neck. 2013;35(8):1189-94.
Szabo Yamashita T, Baky FJ, McKenzie TJ, et.al. Occurrence and Natural History of Thyroid Cancer in Patients with Cowden Syndrome. Eur Thyroid J. 2020;9(5):243-46.
Ekici A. PHACE sendromu. Çarman KB, editör. Nörokütanöz Hastalıklar. 1. Baskı. Ankara: Türkiye Klinikleri; 2021. p.170-6.
Winter PR, Itinteang T, Leadbitter P, Tan ST. PHACE syndrome--clinical features, aetiology and management.Acta Paediatr. 2016;105(2):145-53.
Bongsebandhu-Phubhakdi C, Tempark T, Supornsilchai V. Endocrine manifestations of PHACE syndrome. J Pediatr Endocrinol Metab. 2019;32(8):797-802.
Uihlein LC, Garzon MC, Goodwin G, Liang MG. Growth hormone replacement in patients with PHACE association and hypopituitarism. Pediatr Dermatol 2014;31:337–40.
Altin H, Alp H, Sap F, et al. PHACE syndromevwith growth hormone deficiency and absence of bilateral internalvcarotid arteries: a case report. Pediatr Dermatol 2012;29:316–9.
Merheb M, Hourani R, Zantout MS, Azar ST. Endocrine dysfunction in a patient with PHACE syndrome, including port-wine stain of the right periorbital area. Endocr Pract 2010;16:255–9.
Carinci S, Tumini S, Consilvio NP, et al. A case of congenital hypothyroidism in PHACE syndrome. J Pediatr Endocrinol Metab 2012;25:603–5.
Mamlouk MD, Yu JP, Asch S, Mathes EF. PHACE syndrome and congenitally absent thyroid gland at MR imaging. Clin Imaging 2016;40:237–40.
Huang SA, Tu HM, Harney JW,et al. Severe hypoth yroidism caused by type 3 iodothyronine deiodinase in infantile hemangiomas. N Engl J Med 2000;343:185–9.
